RS61347B1 - Stabilni polipeptidi koji se vezuju za humani komplement c5 - Google Patents

Stabilni polipeptidi koji se vezuju za humani komplement c5

Info

Publication number
RS61347B1
RS61347B1 RS20210005A RSP20210005A RS61347B1 RS 61347 B1 RS61347 B1 RS 61347B1 RS 20210005 A RS20210005 A RS 20210005A RS P20210005 A RSP20210005 A RS P20210005A RS 61347 B1 RS61347 B1 RS 61347B1
Authority
RS
Serbia
Prior art keywords
human complement
polypeptides binding
stable polypeptides
stable
binding
Prior art date
Application number
RS20210005A
Other languages
English (en)
Inventor
Joakim Nilsson
Erik Nordling
Patrik Strömberg
Original Assignee
Ipc Research Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipc Research Llc filed Critical Ipc Research Llc
Publication of RS61347B1 publication Critical patent/RS61347B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
RS20210005A 2013-08-28 2014-08-28 Stabilni polipeptidi koji se vezuju za humani komplement c5 RS61347B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350986 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5
EP14765883.5A EP3038633B1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Publications (1)

Publication Number Publication Date
RS61347B1 true RS61347B1 (sr) 2021-02-26

Family

ID=51539238

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210005A RS61347B1 (sr) 2013-08-28 2014-08-28 Stabilni polipeptidi koji se vezuju za humani komplement c5

Country Status (29)

Country Link
US (1) US9994626B2 (sr)
EP (2) EP3811961A1 (sr)
JP (2) JP6767865B2 (sr)
KR (1) KR102446636B1 (sr)
CN (1) CN105658228B (sr)
AU (1) AU2014314222B2 (sr)
BR (2) BR122023020080A2 (sr)
CA (1) CA2926976C (sr)
CY (1) CY1123732T1 (sr)
DK (1) DK3038633T3 (sr)
ES (1) ES2842105T3 (sr)
HK (1) HK1225656A1 (sr)
HR (1) HRP20210013T1 (sr)
HU (1) HUE052613T2 (sr)
IL (1) IL244218A (sr)
LT (1) LT3038633T (sr)
MX (1) MX2016002397A (sr)
MY (1) MY173804A (sr)
NZ (1) NZ718153A (sr)
PH (1) PH12016500371A1 (sr)
PL (1) PL3038633T3 (sr)
PT (1) PT3038633T (sr)
RS (1) RS61347B1 (sr)
RU (2) RU2020128977A (sr)
SA (1) SA516370622B1 (sr)
SG (1) SG11201602679VA (sr)
SI (1) SI3038633T1 (sr)
UA (1) UA117933C2 (sr)
WO (1) WO2015028558A1 (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
NZ718153A (en) * 2013-08-28 2022-05-27 Ipc Res Llc Stable polypeptides binding to human complement c5
LT3039033T (lt) * 2013-08-28 2019-10-25 Affibody Ab Surišantys polipeptidai, turintys mutuotą karkasą
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
CN111201246B (zh) 2017-07-11 2023-10-27 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2023077139A1 (en) * 2021-11-01 2023-05-04 Ipc Research, Llc Administration of c5-binding proteins

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
EP3031827A1 (en) 2000-10-10 2016-06-15 Genentech, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
ATE360441T1 (de) * 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
EP1667702A2 (en) 2003-09-10 2006-06-14 Baxter International Inc., Baxter Healthcare Corp. Peptides that inhibit complement activation
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
HUE026496T2 (en) * 2006-03-08 2016-06-28 Archemix Llc Complement-binding aptamers and anti-C5 agents for treating eye diseases
ES2612118T3 (es) 2006-03-15 2017-05-12 Alexion Pharmaceuticals, Inc. Tratamiento de pacientes de hemoglobinuria nocturna paroxística mediante un inhibidor del complemento
AU2008281913B2 (en) 2007-07-31 2013-11-07 Affibody Ab New albumin binding compositions, methods and uses
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2231860B1 (en) * 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
AR072897A1 (es) 2008-08-05 2010-09-29 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
NZ604805A (en) * 2010-07-09 2014-09-26 Affibody Ab Polypeptides
WO2013126006A1 (en) * 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
EP2935335B1 (en) 2012-12-19 2020-10-28 Affibody AB New polypeptides
LT3039033T (lt) * 2013-08-28 2019-10-25 Affibody Ab Surišantys polipeptidai, turintys mutuotą karkasą
NZ718153A (en) * 2013-08-28 2022-05-27 Ipc Res Llc Stable polypeptides binding to human complement c5

Also Published As

Publication number Publication date
PL3038633T3 (pl) 2021-07-19
SA516370622B1 (ar) 2018-12-23
WO2015028558A1 (en) 2015-03-05
RU2016111115A3 (sr) 2018-04-25
MY173804A (en) 2020-02-24
UA117933C2 (uk) 2018-10-25
CY1123732T1 (el) 2021-10-29
DK3038633T3 (da) 2021-01-11
RU2016111115A (ru) 2017-10-03
US9994626B2 (en) 2018-06-12
CN105658228A (zh) 2016-06-08
MX2016002397A (es) 2016-09-08
AU2014314222A1 (en) 2016-04-21
NZ718153A (en) 2022-05-27
EP3038633B1 (en) 2020-10-14
RU2020128977A (ru) 2021-11-30
JP6767865B2 (ja) 2020-10-14
AU2014314222B2 (en) 2018-05-24
BR112016003142A2 (pt) 2017-10-17
CA2926976C (en) 2023-11-28
IL244218A0 (en) 2016-04-21
KR102446636B1 (ko) 2022-09-23
CN105658228B (zh) 2020-02-07
BR122023020080A2 (pt) 2023-12-26
PH12016500371B1 (en) 2016-05-02
US20160311870A1 (en) 2016-10-27
EP3811961A1 (en) 2021-04-28
PH12016500371A1 (en) 2016-05-02
KR20160048121A (ko) 2016-05-03
SG11201602679VA (en) 2016-05-30
HUE052613T2 (hu) 2021-05-28
LT3038633T (lt) 2021-03-25
IL244218A (en) 2017-11-30
JP2020172505A (ja) 2020-10-22
ES2842105T3 (es) 2021-07-12
HK1225656A1 (zh) 2017-09-15
JP2016529270A (ja) 2016-09-23
RU2733897C2 (ru) 2020-10-09
CA2926976A1 (en) 2015-03-05
EP3038633A1 (en) 2016-07-06
HRP20210013T1 (hr) 2021-04-02
SI3038633T1 (sl) 2021-05-31
PT3038633T (pt) 2021-01-14

Similar Documents

Publication Publication Date Title
IL267724B (en) Human c5 complement-binding polypeptides
IL275376A (en) Polypeptides with hyperglycosidic bonds
IL240838A0 (en) Anti-3–lag binding proteins
HK1225656A1 (zh) 結合人類補體c5的穩定多肽
HK1218920A1 (zh) 改善的 結合蛋白
ZA201507808B (en) Binding element
ZA201600535B (en) Cosmetic composition
SG11201508627XA (en) Peptides binding to parallel-stranded g-quadruplexes
GB201303977D0 (en) Binding polypeptides
GB201318147D0 (en) Herbal composition
GB201318146D0 (en) Herbal composition
GB201310949D0 (en) Binding Motif